Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%

American Journal of Ophthalmology

Volumn 132, Issue 6, 2001, Pages 860-868

  Orengo Nania, Silvia ^a,c   Landry, Theresa ^b   Von Tress, Mark ^b   Silver, Lewis H ^b   Weiner, Alan ^b   Davis, Alberta A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALCON RESEARCH LTD   (United States)

^c CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; EYE FUNDUS; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; INFLAMMATORY CELL; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHT; OPEN ANGLE GLAUCOMA; OPTIC DISK; OPTIC DISK CUP; PARAMETER; PIGMENTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHEMOTHERAPY, ADJUVANT; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SAFETY; TIMOLOL;

EID: 0035205719     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)01257-0     Document Type: Article

References (21)

1. Vogel R, Crick RP, Newsom RB, Shipley M, Blackmore H, Bulpitt CJ. Association between intraocular pressure and loss of visual field in chronic simple glaucoma. Br J Ophthalmol 1990;74:3-6.
2. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989;107:186-188.
3. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-142.
4. Camras CB. The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103:138-147.
5. Alm A, Stjernschantz J. The Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995;102: 1743-1752.
6. Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther 1999;4:323-333.
7. Sharif, NA, Davis TL, Williams GW. [3H] AL-5848 ([3H] 9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharm Pharmacol 1999;6:685-669.
8. Hellberg MR, Sallee V, McLaughlin M, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin agonist. J Ocular Pharm Ther (To be published).
9. Goh Y, Hotehama Y, Mishima HK. Characterization of ciliary muscle relaxation induced by various agents in cats. Invest Ophthalmol Vis Sci 1995;36:1188-1192.
10. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukarhara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2770-2772.
11. Yousufzai SYK, Ye Z, Abdel-Latif AA. Prostaglandin F2a and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63:305-310.
12. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484.
13. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP: a six-month, masked, multicenter trial. Ophthalmology (To be published).
14. Goldberg I, Vaz JC, Jacobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. Glaucoma 2001;10:414-422.
15. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11:112-116.
16. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in human. Advances in prostaglandin, thromboxane and leucotriene research. Volume 23. New York: Raven Press, Ltd, 1995.
17. Wang YL, Toris CB, Zhan G, Yablonski ME. Effects of topical epinephrine on aqueous humor dynamics in the cat. Exp Eye Res 1999;4:439-445.
18. Alvarado JA, Muryph CG, Franse-Carman L, Chen J, Underwood JL. Effect of beta-adrenergic agonists on paracellular width and fluid flow across outflow pathway cells. Invest Ophthalmol Vis Sci 1998;10:1813-1822.
19. Schenker HI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol 1981;7:1212-1216.
20. The European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority. Document CPMP/EWP/482/99. July 2000.
21. Westfall P, Tobias R, Rom D, Wolfinger R, Hochberg Y. Multiple comparisons and multiple tests using the SAS System. Cary, NC: SAS Institute, 1999:35-37.